109 related articles for article (PubMed ID: 1706915)
41. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases.
Soga J; Tazawa K
Cancer; 1971 Oct; 28(4):990-8. PubMed ID: 4106849
[No Abstract] [Full Text] [Related]
42. Serotonin immunoreactivity in pancreatic endocrine neoplasms (carcinoid tumors).
Wilson RW; Gal AA; Cohen C; DeRose PB; Millikan WJ
Mod Pathol; 1991 Nov; 4(6):727-32. PubMed ID: 1788265
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors.
Kimura N; Pilichowska M; Okamoto H; Kimura I; Aunis D
Mod Pathol; 2000 Feb; 13(2):140-6. PubMed ID: 10697270
[TBL] [Abstract][Full Text] [Related]
44. Effect on in vivo tumorigenicity of lengthy exposure of human colon cancer cells to the differentiation agent hexamethylene bisacetamide.
Schroy P; Winawer S; Friedman E
Cancer Lett; 1989 Nov; 48(1):53-8. PubMed ID: 2819696
[TBL] [Abstract][Full Text] [Related]
45. The differentiation-inducing agent sodium butyrate produces divergent effects on albumin and thyroxine-binding globulin synthesis by human hepatoblastoma-derived (Hep G2) cells.
Bartalena L; Bogazzi F; Donadel G; Martino E; Gabrielli F; Pinchera A
J Endocrinol Invest; 1990 Dec; 13(11):917-22. PubMed ID: 1965315
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of proliferation and induction of differentiation of pluripotent human embryonal carcinoma cells by osteogenic protein-1 (or bone morphogenetic protein-7).
Andrews PW; Damjanov I; Berends J; Kumpf S; Zappavigna V; Mavilio F; Sampath K
Lab Invest; 1994 Aug; 71(2):243-51. PubMed ID: 7521445
[TBL] [Abstract][Full Text] [Related]
47. [Effects of hexamethylene bisacetamide on related genes expression of apoptosis and cell proliferating in human mucoepidermoid carcinoma cell line MEC-1].
Wang L; Wang J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2002 Mar; 37(2):120-2. PubMed ID: 12475424
[TBL] [Abstract][Full Text] [Related]
48. Sodium butyrate inhibits rat insulinoma cell proliferation without affecting the cellular insulin content or insulin release.
Sjöholm A
Anticancer Drugs; 1993 Apr; 4(2):259-63. PubMed ID: 8490204
[TBL] [Abstract][Full Text] [Related]
49. [Influence of sodium butyrate on growth of HT-29 colon carcinoma cells and expression of inducible nitric oxide synthase (iNOS)].
Li F; Luo HS; Ding YJ; Li X
Ai Zheng; 2004 Apr; 23(4):416-20. PubMed ID: 15087030
[TBL] [Abstract][Full Text] [Related]
50. [Effects of hexamethylene bisacetamide on in vitro adhesion, motility and invasion of human mucoepidermoid carcinoma cell line MEC-1].
Liu B; Wu J; Situ Z
Zhonghua Kou Qiang Yi Xue Za Zhi; 2000 May; 35(3):197-9. PubMed ID: 11780223
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model.
Engelhard HH; Duncan HA; Kim S; Criswell PS; Van Eldik L
Neurosurgery; 2001 Mar; 48(3):616-24; discussion 624-5. PubMed ID: 11270553
[TBL] [Abstract][Full Text] [Related]
52. Sodium butyrate-induced alteration of growth properties and glycogen levels in cultured human colon carcinoma cells.
Dexter DL; Lev R; McKendall GR; Mitchell P; Calabres P
Histochem J; 1984 Feb; 16(2):137-49. PubMed ID: 6698802
[TBL] [Abstract][Full Text] [Related]
53. Ultrastructural differentiation and CEA expression of butyrate-treated human pancreatic carcinoma cells.
el-Deriny SE; O'Brien MJ; Christensen TG; Kupchik HZ
Pancreas; 1987; 2(1):25-33. PubMed ID: 3575313
[TBL] [Abstract][Full Text] [Related]
54. The modulation of growth by HMBA in PKC overproducing HT29 colon cancer cells.
Choi PM; Weinstein IB
Biochem Biophys Res Commun; 1991 Dec; 181(2):809-17. PubMed ID: 1755860
[TBL] [Abstract][Full Text] [Related]
55. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Rowinsky EK; Donehower RC; Spivak JL; Burke PJ; Griffin CA; Jones RJ
J Natl Cancer Inst; 1990 Dec; 82(24):1926-31. PubMed ID: 2250314
[TBL] [Abstract][Full Text] [Related]
56. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
57. Modulation of cellular proliferation alters glutamine transport and metabolism in human hepatoma cells.
Bode BP; Souba WW
Ann Surg; 1994 Oct; 220(4):411-22; discussion 422-4. PubMed ID: 7944654
[TBL] [Abstract][Full Text] [Related]
58. Modulation by sodium butyrate of the differentiated status of a clonal pancreatic B-cell line (RIN).
Gardner SL; Dotta F; Nayak RC; George KL; Eisenbarth GS; Halban PA
Diabetes Res; 1989 Oct; 12(2):93-9. PubMed ID: 2699445
[TBL] [Abstract][Full Text] [Related]
59. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
60. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro.
Vitale G; de Herder WW; van Koetsveld PM; Waaijers M; Schoordijk W; Croze E; Colao A; Lamberts SW; Hofland LJ
Cancer Res; 2006 Jan; 66(1):554-62. PubMed ID: 16397272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
